OBJECTIVES To design a user-friendly cost calculator to estimate and project health care costs of patients diagnosed with hepatitis C virus (HCV) infection in Turkey. METHODS We used Visual Basic in a Microsoft Excel to program complicated models within an easy-to-use framework for providers and payers to calculate pharmacy costs for HCV patients in Turkey. The calculator, first, uses the starting year to the end year as an input. The user then enters prevalent and incident patient numbers. Medication types, medication names, prescription numbers per year and prescription costs per medication are also entered. The calculator allows combination therapies. Depending on response rates, rates of incident and prevalent patients and medications type, prescription rates from 2014 and forward (until 2020) can then be calculated and projected. The calculator can be used for any country as long as the inputs are available through literature from real-world or simulation studies.  RESULTS We used a hypothetical example to project pharmacy costs in Turkey in 2014 and 2015. We assumed 10,000 patients in 2014 (20% were assumed to be treatment naïve) and expected 2,000 new patients in 2015. We assumed ribavirin and telaprevir combination therapy for 2014 treatment naïve patients, and peginterferon alfa-2a and ribavirin for prevalent patients. The response and treatment rates were assumed at 80% for patients who were eligible for treatment. The recurrence rate was assumed to be approximately 10% after treatment. Pharmacy costs for HCV were calculated at €7 million in 2014 and approximately €2 million in 2015, using these rates.  CONCLUSIONS The economic burden of HCV in Turkey is significant. A simple-to-use calculator that uses real-world data and econometric models to estimate health care costs of patients with HCV can help payers and providers to make improved evidence-based health care decisions.